drugset / Trial / NCT03638960

Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery

NCT03638960 ↗

Phase 4 Completed 40 enrolled University of Southern California
RandomizedParallel-groupDouble-blindTreatment

Summary

The investigators will be comparing pain scores and opioid use in patients receiving interscalene peripheral blocks with plain bupivacaine versus those receiving liposomal bupivacaine. Liposomal bupivacaine is described as releasing local anesthetic up to 72 hours after its injection; therefore if liposomal bupivacaine can provide extended pain relief compared to plain bupivacaine, the investigators can consider using it as our primary local anesthetic. As secondary outcomes, the investigators will also be looking at difference in functional status and long-term differences between the two local anesthetics.

Timeline

Start
2019-02-21
Primary completion
2023-01-11
Completion
2023-06-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.5 % Other
Subject Bupivacaine Other / unclassified 10 ml Other
Subject Bupivacaine Other / unclassified 20 ml Other
Subject Bupivacaine Other / unclassified 133 mg Other

Indications